Focus Area update: Diabetes, Obesity and Metabolism
ESE Focus Area Update:
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism: the latest advances
Welcome to the first ESE Newsletter of the Focus Area Diabetes, Obesity and Metabolism. Basic, translational and clinical research in the breadth of our Focus Area is progressing rapidly. It offers basic researchers, as well as clinicians, new insights into the pathophysiology of these widespread diseases and development of new therapeutic strategies. At the same time, it offers patients the opportunity to improve their quality of life, reduce the burden of diseases associated with diabetes, obesity and metabolic disorders, as well as prolonging their life.
In this first Newsletter, we aim to provide relevant information on research and meetings related to our Focus Area. We list selected, relevant publications and shed light on new studies that have the potential to augment the therapeutic armamentarium to fight the increasing prevalence of metabolic disorders, as well as providing guidance on the endocrine work-up of obese patients. We hope that you will find something that matches your interests and that you will enjoy our selections.
Anton Luger and Daniela Cota
Guest Editors ESE Focus Area for Diabetes, Obesity and Metabolism
Designing a new therapy against type 2 diabetes
Mark Febbraio and colleagues have engineered a
chimeric cytokine, called IC7Fc, which has CNTF-like, but IL-6-receptor-dependent, signaling. IC7Fc shows potent therapeutic effects in preclinical models of obesity and type 2 diabetes, while being devoid of inflammatory activity and immunogenicity, which are side effects that have halted the therapeutic use of CNTF or IL-6 analogues in the past.
Alternate day fasting and its impact on metabolism in healthy humans
Alternate day fasting has become a popular weight loss strategy. In a randomised controlled trial, Madeo and colleagues now demonstrate that this strategy (36-hour water fast and 12-hour feast) is safe and effective in reducing body weight and metabolic disease risk in healthy, non-obese subjects.
Prevalence of hypercortisolism in patients with obesity: 0.87%.
Drug for the treatment of overactive bladder increases metabolic activity and improves glucose homeostasis
Two US studies from the National Institutes of Health, Bethesda, MD and the University of Kentucky, KY, report that the β3-adrenergic receptor agonist Mirabegron, which is approved only for the treatment of overactive bladder, increases brown adipose tissue activity, HDL cholesterol and adiponectin plasma concentrations, as well as improving insulin sensitivity in healthy volunteers. The latter beneficial effect is also observed in obese, insulin-resistant subjects. The authors suggest that β3-adrenergic receptor agonists should be further investigated as treatment for metabolic diseases.
PAPERS OF INTEREST
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Day EA, et al., Nat Metab. (Dec 2019) Full article
Microglial UCP2 Mediates Inflammation and Obesity Induced by High-Fat Feeding. Kim JD, et al., Cell Metab. (Nov 2019) Full article
Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Sun X, et al., Cell Metab (Jan 2020) Full article
Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis. Orodnik M, et al., Cell Metab (May 2019) Full article
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Neal B, et al., N Engl J Med. (Jun 2019) Full article
Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure. Aminian A, et al., Diabetes Care (Jan 2020) Full article
Effects of Bariatric Surgery in Early- and Adult-Onset Obesity in the Prospective Controlled Swedish Obese Subjects Study. Kristensson FM, et al., N Engl J Med. (Jan 2020) Full article
The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. Anderson SM, et al., Diabetes Technol Ther. (Feb 2019) Full article
Trends in cancer mortality among people with vs without diabetes in the USA, 1988-2015. Harding JL, et al., Diabetologia (Jan 2020) Full article
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Picke AK, et al., Endo Connect. (Mar 2019) Full article
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. Ghosh RK, et al., Am J Cardiol. (Dec 2019) Full article
Inter-organ cross-talk in metabolic syndrome. Priest C & Tontonoz P, Nature Metab. (Dec 2019) Full article
4 March 2020, World Obesity Day
15 - 16 May 2020, European Conference on Rare Diseases & Orphan Products (ERCD), Stockholm, Sweden
17 - 20 May 2020, European and International Congress on Obesity, Dublin, Ireland
12 - 16 June 2020, 80th Scientific Sessions of the American Diabetes Association (ADA), Chicago, USA
21 - 25 Sep 2020, 56th Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna, Austria
European Society of Endocrinology
Starling House, 1600 Bristol Parkway North, Bristol BS34 8YU
You are receiving this email because you signed up to our mailing list or at some point have worked with us. This email and any files transmitted with it are intended solely for the use of the individual or entity to whom they are addressed, and may contain confidential information. If you have received this e-mail in error please notify firstname.lastname@example.org. If you no longer wish to receive these emails, you can unsubscribe instantly.